Brawley, O. W., Cornelius, L. J., Edwards, L. R., Gamble, V. N., Green, B. L., Inturrisi, C., … Schori, M. (2008). National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. Ann Intern Med, 148(12), 932–938. https://doi.org/10.7326/0003-4819-148-12-200806170-00220

Brawley, Otis W., Llewellyn J. Cornelius, Linda R. Edwards, Vanessa Northington Gamble, Bettye L. Green, Charles Inturrisi, Andra H. James, et al. “National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease.” Ann Intern Med 148, no. 12 (June 17, 2008): 932–38. https://doi.org/10.7326/0003-4819-148-12-200806170-00220.

Brawley OW, Cornelius LJ, Edwards LR, Gamble VN, Green BL, Inturrisi C, et al. National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. Ann Intern Med. 2008 Jun 17;148(12):932–8.

Brawley, Otis W., et al. “National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease.” Ann Intern Med, vol. 148, no. 12, June 2008, pp. 932–38. Pubmed, doi:10.7326/0003-4819-148-12-200806170-00220.

Brawley OW, Cornelius LJ, Edwards LR, Gamble VN, Green BL, Inturrisi C, James AH, Laraque D, Mendez M, Montoya CJ, Pollock BH, Robinson L, Scholnik AP, Schori M. National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. Ann Intern Med. 2008 Jun 17;148(12):932–938.